Mitogen-activated protein kinase signaling pathways and osteoclast-associated genes (MAPK/Osteoclast Genes)

The Mitogen-Activated Protein Kinase (MAPK) signaling pathways and osteoclast-associated genes represent a complex regulatory network essential for bone remodeling and homeostasis [1]. This system is primarily activated by the binding of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) to its receptor RANK, which triggers the p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) cascades [2]. These pathways converge to induce the expression of the master transcription factor NFATc1, which subsequently activates a suite of osteoclast-associated genes including Tartrate-resistant acid phosphatase (TRAP), Cathepsin K (CTSK), and the Calcitonin receptor [3]. Dysregulation of this signaling axis is a primary driver of pathological bone loss in diseases such as osteoporosis, rheumatoid arthritis, and metastatic bone disease [4]. While the pathway itself is a broad biological concept rather than a single drug target, specific components like RANKL are successfully targeted by drugs like denosumab to inhibit osteoclastogenesis and preserve bone density [5]. Additionally, small-molecule inhibitors of specific MAPKs, such as p38 inhibitors, have been investigated in clinical trials for inflammatory bone diseases, although systemic toxicity remains a challenge [1][4].

Other names

MAPK cascade in osteoclastogenesisRANKL-induced MAPK signalingOsteoclastogenic gene programMAPK-NFATc1 signaling axis

Inhibition of the RANKL/RANK axis or specific downstream kinases (p38, ERK, JNK) to prevent the induction of NFATc1 and other osteoclast-specific genes, thereby reducing bone resorption [1][2].